These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11595538)

  • 1. Osteosarcoma risk in rats using PTH 1-34.
    Barbehenn EK; Lurie P; Wolfe SM
    Trends Endocrinol Metab; 2001 Nov; 12(9):383. PubMed ID: 11595538
    [No Abstract]   [Full Text] [Related]  

  • 2. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
    Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
    Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
    Andrews EB; Gilsenan A; Midkiff K; Harris D
    Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
    Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
    Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
    Kuijpers G; Schneider B; Stadel B; Colman E
    BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
    [No Abstract]   [Full Text] [Related]  

  • 6. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
    Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
    Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84).
    Tashjian AH; Goltzman D
    J Bone Miner Res; 2008 Jun; 23(6):803-11. PubMed ID: 18435577
    [No Abstract]   [Full Text] [Related]  

  • 8. The activation of cAMP-dependent protein kinase is directly linked to homologous desensitization by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells.
    Sugimoto T; Kano J; Fukase M; Fujita T
    Horm Metab Res; 1992 Jul; 24(7):347-8. PubMed ID: 1325405
    [No Abstract]   [Full Text] [Related]  

  • 9. [Fluorides and osteosarcoma: human experience is reassuring but need a careful interpretation].
    Valiquette L; Kosatsky T; Armstrong B
    Can J Public Health; 1992; 83(1):75-7. PubMed ID: 1571889
    [No Abstract]   [Full Text] [Related]  

  • 10. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
    Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
    J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTH analogues and osteoporotic fractures.
    Verhaar HJ; Lems WF
    Expert Opin Biol Ther; 2010 Sep; 10(9):1387-94. PubMed ID: 20629581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The participation of the activation of cAMP-dependent protein kinase in cytosolic acidification by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells.
    Sugimoto T; Kano J; Fukase M; Fujita T
    Horm Metab Res; 1992 Sep; 24(9):448-9. PubMed ID: 1427618
    [No Abstract]   [Full Text] [Related]  

  • 13. Osteosarcoma and teriparatide?
    Harper KD; Krege JH; Marcus R; Mitlak BH
    J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
    [No Abstract]   [Full Text] [Related]  

  • 14. [Osteosarcoma induced in rabbits by 4-nitroquinoline-1-oxide].
    Huang CD; Li ZS; Liu ZJ
    Zhonghua Wai Ke Za Zhi; 1987 Dec; 25(12):691-2, 733. PubMed ID: 3133181
    [No Abstract]   [Full Text] [Related]  

  • 15. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
    Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
    J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
    Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
    J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caution needed in fluoride and osteosarcoma study.
    Douglass CW; Joshipura K
    Cancer Causes Control; 2006 May; 17(4):481-2. PubMed ID: 16596300
    [No Abstract]   [Full Text] [Related]  

  • 18. Second messenger signaling in the regulation of cytosolic pH and DNA synthesis by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: role of Na+/H+ exchange.
    Sugimoto T; Kano J; Fukase M; Fujita T
    J Cell Physiol; 1992 Jul; 152(1):28-34. PubMed ID: 1320038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Is it possible to utilize experimental osteosarcoma in clinical practice?].
    Kalman E
    Bratisl Lek Listy; 1970 Oct; 54(4):401-6. PubMed ID: 5273737
    [No Abstract]   [Full Text] [Related]  

  • 20. National Toxicology program report on fluoride and cancer.
    Gabler WL
    J Oreg Dent Assoc; 1991; 60(4):32-3. PubMed ID: 1856781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.